The increased susceptibility to seasonal influenza coupled with decreased vaccine efficacy among older adults, who make up the fastest growing population in the United States, constitutes an emerging public health crisis. The Live Attenuated Influenza Vaccine (LAIV) is a nasally administered vaccine that has been shown to be more effective than the trivalent inactivated vaccine (TIV) in pediatric populations due to its ability to replicate and elicit a mucosal immune response at the site of natural infection - the nasal epithelium. Our preliminary data demonstrate that the LAIV exhibits significantly less replication in human nasal epithelial cell (hNEC) cultures from adults over 65 compared with younger subjects. Inadequate infection of the nasal epithelium limits the vaccine-activated immune response and we hypothesize that decreased LAIV infection and replication in the nasal epithelium of older adults contributes to the reduced vaccination efficacy. This proposal aims to characterize the defect in LAIV infection of nasal epithelial cells from older adults by comparing virus replication and nasal epithelial cell immune responses between adults over 65 and younger subjects between the ages of 5 and 17. The functional significance of any differences in the epithelial cell-derived immune responses between younger and older hosts will be assessed in order to identify potential mechanisms at the level of the epithelium, which modulate immune responses to the LAIV. Then we will study the effect of aging on the interaction between hNECs and dendritic cells in order to gain insight into how these age-specific changes in LAIV replication and nasal epithelial immune responses affect the dendritic cell-initiated adaptive immune response. The ultimate goal of this project is to identify age-specific epithelial cell factors that affect virus replication, which can then be used in the development of either novel vaccines with expanded immunoprotection or immune-modulatory adjuvants that can improve vaccine efficacy in older adults by enhancing vaccine replication.

Public Health Relevance

The increased susceptibility to seasonal influenza coupled with decreased vaccine efficacy among older adults constitutes an emerging public health crisis. The Live Attenuated Influenza Vaccine is the most effective vaccine in pediatric populations but is not protective in older adults. The reason the LAIV is believed to work so well in children but not in older adults is that it can replicate well in the nose of children and stimulate a protectiv immune response whereas in older adults the lack of adequate replication fails to elicit an effective immune response. The primary goal of this proposal is to further our understanding of how aging affects LAIV efficacy in older adults by identifying the epithelial cell specific factors that inhibit vaccine replication in older adults which will lead to the development of novel strategies designed to improve vaccine efficacy in older adults through enhanced vaccine replication.

Agency
National Institute of Health (NIH)
Type
Small Research Grants (R03)
Project #
5R03AG045088-02
Application #
8719907
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Salive, Marcel
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Fletcher, Tom E; Fischer 2nd, William A; Jacob, Shevin T (2016) Convalescent Plasma for Ebola Virus Disease. N Engl J Med 374:2499-500
Fischer 2nd, William A; Wohl, David A (2016) Confronting Ebola as a Sexually Transmitted Infection. Clin Infect Dis 62:1272-6
Fischer, William A; Wohl, David A (2016) Responding to the Global Threat of High-Consequence Pathogens: Protecting Health Care Workers and Caring for Patients. Ann Am Thorac Soc 13:584-5
Fischer 2nd, William A; King, Landon S; Lane, Andrew P et al. (2015) Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells. Vaccine 33:4495-504
Fischer 2nd, William A; Weber, David J; Wohl, David A (2015) Personal Protective Equipment: Protecting Health Care Providers in an Ebola Outbreak. Clin Ther 37:2402-10
Bah, Elhadj Ibrahima; Lamah, Marie-Claire; Fletcher, Tom et al. (2015) Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372:40-7
Fischer 2nd, William A; Uyeki, Timothy M; Tauxe, Robert V (2015) Ebola virus disease: What clinicians in the United States need to know. Am J Infect Control 43:788-93
Fischer 2nd, William A; Chason, Kelly D; Brighton, Missy et al. (2014) Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures. Vaccine 32:1761-7
Fischer 2nd, William A; Gong, Michelle; Bhagwanjee, Satish et al. (2014) Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart 9:325-36
Müller, Loretta; Brighton, Luisa E; Carson, Johnny L et al. (2013) Culturing of human nasal epithelial cells at the air liquid interface. J Vis Exp :